U.S. FDA Approves CSL Behring’s IDELVION® — The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals
In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00 IDELVION, CSL Behring’s long-acting recombinant albumin fusion protein, delivers on the company’s promise to develop and provide innovative specialty biotherapies